Stocks
Nektar Therapeutics (NKTR) EBITDA margin US GAAP (year values) |
||||||||
| 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
| EBITDA margin, % | ? | -257.9% | -454.3% | -353.6% | -351.8% | -269.8% | -147.9% | |
| Changes by years, y/y, % | +76pp | -196pp | +101pp | +2pp | +82pp | |||
Nektar Therapeutics. EBITDA margin, %
Nektar Therapeutics. EBITDA margin, changes, pp
Nektar Therapeutics (NKTR) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | -158.6% | -140.6% | -137.2% | -189.2% | -124.5% | -147.9% | |
| Changes by years, y/y, % | -20pp | +31pp | +15pp | -50pp | +34pp | |||
| Changes by quarters, q/q, % | -20pp | +18pp | +3pp | -52pp | +65pp | |||
